logo

JobNob

Your Career. Our Passion.

Director, Channel Accounts


Intercept Pharmaceuticals


Location

Morristown, NJ | United States


Job description

POSITION SUMMARY:

As Intercept continues to build its position as the leader in rare and serious liver disease, we are seeking a Director, Channel Accounts.

As a key member of the U.S. Market Access team, the Director of Channel Accounts (DCA) will be responsible for partnering with internal and external stakeholders to help develop and manage the U.S. channel strategy that will provide access and therapy management services for Intercept’s products to patients. The DCA will report directly into the Senior Director of U.S. Patient Services & Channel Operations. This individual will have responsibility for helping the Senior Director in creating Intercept’s distribution concept, value proposition, and managing contracts of specialty pharmacy vendors. The successful outcome is a channel and distribution strategy that will economically provide seamless product distribution, complete data collection and guarantee product integrity/pedigree. Success will be driven through alignment of the strategies with defining critical success factors, key performance indicators (conversions, adherence, time to fill, etc.), and the supporting tactics for Intercept’s products. This individual will need to work closely with the Senior Director and interface with Strategic Accounts, Patient Services, Reimbursement Access Managers, Supply Chain, Sales, Marketing, Legal, Medical Science Liaison (MSL), Analytics and Commercial Operations teams on a routine basis to ensure alignment in a fast-paced matrix environment.

CORE ACCOUNTABILITIES:

The successful candidate must be able to perform each of the following satisfactorily, with or without an accommodation:

Requirements

QUALIFICATIONS:

REQUIRED KNOWLEDGE AND ABILITIES:

Benefits

COMPANY CULTURE:

People at Intercept are passionate about patients. You’ll see our patient photos lining our walls and hear their stories in town halls. We’re equally passionate about our team and ensuring each member from all dimensions of diversity feels included and has the opportunity to reach their potential. We recognize the power of a diverse, equitable and inclusive (DEI) work force, and how it enriches the professional lives of our team members. Diversity, Equity, and Inclusion drives innovation and connects us to the patients and communities we serve.

As we grow, we want to make every effort to provide a safe and open environment for professionals of every background and provide knowledge on how to work inclusively and equitably to make Intercept a great place to work.

At Intercept, we foster an environment that celebrates creativity, collaboration, and mutual respect. We never hesitate to lean on our teammates and work together. Our relatively small size means you partner with accessible leaders who know you by name. This brings accountability and growth, which all add up to more opportunities to learn something new every day. For self-motivated leaders who are ready to make a di¬fference in the lives of patients, Intercept is a great place to be.

COMPANY SUMMARY:

At Intercept, our mission is to build a healthier tomorrow for patients with rare and serious liver diseases. Intercept’s lead product, obeticholic acid (OCA), is a first-in-class farnesoid X receptor (FXR) agonist marketed under the brand name “Ocaliva®” in the U.S., EU and Canada for the treatment of patients with primary biliary cholangitis (PBC), a rare autoimmune liver disease. In 2016, Ocaliva® was the first medication to be approved for PBC in over twenty years, and sales continue to grow.

Intercept continues to build on our ongoing commitment to people living with PBC by progressing our research portfolio with a novel fixed-dose combination of OCA and bezafibrate. The first Phase 2 interim analysis of this combination was presented at the European Association for the Study of the Liver (EASL) congress in June of 2023. Further, we are leveraging our decades of research and background in bile acids and FXR agonism to expand our pipeline in other liver diseases, such as severe alcohol-associated hepatitis (sAH).

COMPENSATION & BENEFITS:

The anticipated starting salary range for this position is $190,000 to $255,000. This represents the anticipated low and high end of the salary range for this position. Actual salaries will vary and may be above or below the range, based on various factors including, but not limited to, experience, skillset, and performance.

The salary range listed is just one component of our total compensation package. Successful applicants will also be eligible to receive annual bonuses at the discretion of the Company. Intercept also provides a competitive suite of benefits, including:

EEO Statement

Employment decisions at the Company are made without unlawful regard to race, color, religion, creed, national origin, alienage or citizenship status, sex (including gender, pregnancy, childbirth or medical conditions related to pregnancy or childbirth), gender identity or expression, sexual orientation, national origin, ethnicity, age, physical or mental disability, legally protected genetic information, marital or partnership status, sexual and reproductive health decisions, military or veteran status, or any other status protected by applicable federal, state, or local law. This organization participates in E-Verify (E-Verify's Right to Work guidance can be found here:

#LI-JJ1


Job tags

Holiday workFull timeTemporary workInterim roleLocal area


Salary

All rights reserved